Previous studies on SGLT2 inhibitor administration in humans have confirmed the safety and efficacy of SGLT2 inhibitors for the treatment of T2DM; thus, SGLT2 inhibitors are primarily recommended for the treatment of patients with T2DM. Here, SLC5A2 is linked to type 2 diabetes mellitus.